PATENT CLAIM ANALYSIS

Application Number: 16155841
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-04
Patent Classification: ["514", "224200"]

Abstract:
Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

Claim (Index 53):
The method of  claim 47 , comprising selecting the individual for treatment based on (i) the presence of one or more mutations in the TP53 gene in the cancer, or (ii) expression of mutant p53 in the cancer.

Metadata:
- Claim Count in Document: 61.0
- Percentile: 97.0
- Lexical Diversity: 1.26087
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13406937', '13547314', '13655164', '14307680', '14748990']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.788837461429386
- 35 USC 102 Novelty (BERT): 0.5326628534727402
- Combined Prediction Score: 0.7632200006337215
- Mean Citation Score: 312.78887999999995
- Max Citation Score: 325.19232
- Similarity Product: 144.4532032708168

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test